Hydrochlorothiazide

Generic Name: Hydrochlorothiazide

Brand Names: Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈ClN_₃O_₄S_₂

CAS Number: 58-93-5

Unique Ingredient Identifier: 0J48LPH2TH

Background: Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication: Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions: Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Clinical Trials

ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling

Phase 4

Completed

Conditions: Hypertension
Left Ventricle Hypertrophy

Interventions: Drug: Aliskiren
Drug: Losartan
Drug: Amlodipine
Drug: Hydrochlorothiazide (HCTZ)

First Posted Date: 2010-08-05

Last Posted Date: 2014-07-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT01176032

Locations: 🇪🇸
Novartis Investigative Site, Santander, Spain

Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency

Phase 4

Completed

Conditions: Hypertension
Renal Insufficiency

Interventions: Drug: Hydrochlorothiazide
Drug: Indapamide

First Posted Date: 2010-07-29

Last Posted Date: 2014-06-24

Lead Sponsor: West China Hospital

Target Recruit Count: 240

Registration Number: NCT01172431

Locations: 🇨🇳
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Losartan potassium/Hydrochlorothiazide
Drug: Hyzaar®

First Posted Date: 2010-06-23

Last Posted Date: 2010-12-08

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 20

Registration Number: NCT01149486

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Treatment of Adiposity Related hypErTension (TARGET)

Phase 4

Completed

Conditions: Hypertension
Abdominal Obesity
Metabolic Syndrome

Interventions: Drug: Hydrochlorothiazide
Drug: Aliskiren
Drug: Moxonidine
Drug: Placebo (for moxonidine and hydrochlorothiazide)
Drug: Placebo (for aliskiren)

First Posted Date: 2010-06-07

Last Posted Date: 2012-02-24

Lead Sponsor: UMC Utrecht

Target Recruit Count: 32

Registration Number: NCT01138423

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands

Aldosterone and the Metabolic Syndrome

Phase 1

Completed

Conditions: Diabetes Mellitus
Metabolic Diseases
Glucose Metabolism Disorders
Endocrine System Diseases

Interventions: Drug: Hydrochlorothiazide (HCTZ)
Drug: Aliskiren 150 mg (ALI 150)
Drug: Aliskiren 300 mg (ALI 300)
Drug: Spironolactone (SPL 25)
Drug: Spironolactone 50 mg (SPL 50)

First Posted Date: 2010-04-14

Last Posted Date: 2018-11-05

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 69

Registration Number: NCT01103245

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2
Hypertension

Interventions: Drug: Placebo to Ertuglilflozin 1 or 5 mg
Drug: Ertugliflozin 1 mg
Drug: Ertugliflozin 5 mg
Drug: Placebo to HCTZ
Drug: Ertugliflozin 25 mg
Drug: HCTZ 12.5mg
Drug: Placebo to ertuglilflozin 25 mg

First Posted Date: 2010-03-31

Last Posted Date: 2018-09-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 194

Registration Number: NCT01096667

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan 40mg
Drug: Telmisartan 80mg
Drug: Hydrochlorothiazide 12.5mg

First Posted Date: 2010-01-15

Last Posted Date: 2014-05-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1452

Registration Number: NCT01050062

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site 234, Akashi, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 237, Amagasaki, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 141, Chigasaki, Japan

and more 311 locations

Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial

Phase 4

Completed

Conditions: Blood Pressure

Interventions: Drug: amlodipine 5/10 mg per day plus valsartan 160 mg/day
Drug: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day

First Posted Date: 2009-12-11

Last Posted Date: 2013-12-09

Lead Sponsor: KU Leuven

Target Recruit Count: 183

Registration Number: NCT01030458

Locations: 🇳🇬
University of Enugu, Enugu, Nigeria
🇬🇦
Hôpital Central Universitaire de Libreville, Libreville, Gabon
🇸🇳
Hôpital Aristide Le Dantec, Dakar, Senegal

and more 4 locations